NCT07002112View on ClinicalTrials.gov

The LVIVO-TaVec100 Product in the Treatment of Relapsed/Refractory B-cell Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 23, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2029

Conditions
Relapsed/Refractory B-cell Malignancies
Interventions
BIOLOGICAL

LVIVO-TaVec100 product

Prior to infusion of the LVIVO-TaVec100 product, subjects will receive bridging therapy if needed.

Trial Locations (6)

102206

RECRUITING

Beijing Gobroad Boren Hospita, Beijing

210029

RECRUITING

The First Affiliated Hospital with Nanjing Medical University, Nanjing

230000

RECRUITING

The First Affiliated Hospital of USTC west district, Hefei

430000

RECRUITING

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

450000

NOT_YET_RECRUITING

The First Affiliated Hospital of ZHENGZHOU University, Zhengzhou

050000

RECRUITING

The Fourth Hospital of Hebei Medical University, Shijiazhuang

Sponsors
All Listed Sponsors
collaborator

Nanjing Legend Biotech Co.

INDUSTRY

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER